Skip to content
- Bharat Biotech International Ltd launched Hillchol (BBV131) on August 27, 2024.
- Hillchol (BBV131) is a novel single-strain oral cholera vaccine (OCV).
- Bharat Biotech has developed it under licence from Hilleman Laboratories (funded by Merck, USA and Wellcome Trust, UK).
- Around the world, there is a lack of OCVs. There is now just one manufacturer supplying OCVs all over the world.
- Currently, there is an annual shortage of about 40 million doses.
- Every year, more than 100 million doses of the vaccine are required worldwide.
- Large-scale manufacturing facilities have been set up by Bharat Biotech in Bhubaneswar and Hyderabad.
- The facilities can generate 200 million doses of Hillchol.
- Hyderabad facility has a 45 million dose capacity, with the remaining portion will be in Bhubaneswar.
- The oral Hillchol vaccination is given in two doses on Days 0 and 14.
- Children older than a year old can use it. It will be offered as a respule with a single dose. The recommended storage range is plus 2 to 8°C.
- Hillchol is presented in a mono-multidose format. This is one of the first such presentations for vaccines.
error: Content is protected !!
